Antipsychotic Drugs

Encyclopedia of Neuroscience

Volumn , Issue , 2009, Pages 487-492

  McEvoy, J P ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Antipsychotic drugsAripiprazoleAtypical antipsychotic drugsChlorpromazineClozapineNeurolepticsOlanzapinePerphenazinePsychosisQ uetiapineRisperidoneSchizophreniaZiprasidone

Indexed keywords

EID: 84855386978     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-008045046-9.00375-2     Document Type: Chapter

References (16)

1. Tardive Dyskinesia 1992, A Task Force, Report of the American Psychiatric Association (1992), American Psychiatric Association, Washington, DC.
2. Csernansky J.G., Mahmoud R., Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 2002, 346:16-22.
3. Davis J.M., Chen N., Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003, 60:553-564.
4. Kapur S., Zipursky R., Jones C., et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry 2000, 157:514-520.
5. Geddes J., Freemantle N., Harrison P., et al. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Medical Journal 2000, 321:1371-1376.
6. Grace A.A., Bunney B.S., Moore H., et al. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends in Neuroscience 1997, 20:31-37.
7. Haase H.J., Janssen P.A.J. The Action of Neuroleptic Drugs 1985, Elsevier Science Publishing Company, New York.
8. Healy D., Savage M. Reserpine exhumed. British Journal of Psychiatry 1998, 172:376-378.
9. Schizophrenia, Part Three: Physical Treatments 2003, Blackwell Publishing, Oxford. S.R. Hirsch, D.R. Weinberger (Eds.).
10. Jones P.B., Barnes T.R., Davies L., et al. Randomized controlled trial of the effect an quality of life of second-vs first-generation antipsychotic drugs in schizophrenia (CUtLASS 1). Archives of General Psychiatry 2006, 63:1079-1087.
11. Kane J., Honigfeld G., Singer J., et al. Clozapine for the treatment-resistant schizophrenic; a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988, 45:789-796.
12. Leucht S., Barnes T.R., Kissling W., et al. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry 2003, 160:1209-1222.
13. Leucht S., Wahlbeck K., Hamann J., et al. New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis. Lancet 2003, 361:1581-1589.
14. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Effectiveness of antipsychotic drugs in patients with schizophrenia. New England Journal of Medicine 2005, 353:1209-1223.
15. McEvoy J.P., Hogarty G.E., Steingard S. Optimal dose of neuroleptic in acute schizophrenia: A controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry 1991, 48:739-745.
16. Volavka J., Czobor P., Sheitman B., et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry 2002, 159:255-262.